Thymidine phosphorylase expression is associated with time to progression in patients receiving low-dose, docetaxel-modulated capecitabine for metastatic breast cancer

摘要: Abstract Background Preclinical data have indicated a synergistic interaction between docetaxel and capecitabine by means of taxane-induced up-regulation thymidine phosphorylase (TP). On the basis such premises, we conducted phase II trial to determine activity tolerability weekly plus in patients with metastatic breast cancer (MBC). Furthermore, explored relationship TP tumor expression benefit from this regimen. Patients methods received 36 mg/m2 i.v. on days 1, 8, 15 orally 625 b.i.d. 8 21. Cycles were repeated every 4 weeks. In correlative study, evaluated immunohistochemistry messenger RNA real-time RT–PCR primary tumor. Results Forty-seven women enrolled. intention-to-treat analysis, objective responses achieved 24 (51%). Fourteen additional (30%) had stable disease. The median time progression (TTP) was 6 months (range 1–44 months). Median survival 17 1–48 Overall, treatment well tolerated. most common clinical adverse events (all grades) alopecia (55%), nail changes (53%), fatigue/asthenia (51%), nausea/vomiting neutropenia (49%), neuropathy (49%). A significantly higher TTP observed TP-positive tumors (log-rank test, P = 0.009). Interestingly, subgroup analysis confirmed obtaining response 0.03), whereas statistical significance lost nonresponders 0.3). Conclusions This study indicates that regimen low doses is active against MBC. provides preliminary evidence may be predictive marker for therapeutic benefit.